

Konica Minolta, Inc. 4th Quarter/FY2021 ended in March 2022 Consolidated Financial Results


Toshimitsu Taiko

President and CEO

Three months : January 1, 2022 – March 31, 2022

Fiscal Year 2021 : April 1, 2021 - March 31, 2022

- Announced on May 12, 2022 -



Putting Konica Minolta on Track to Renewed Growth as President



Vision

 Under our vision, "Imaging to the People," we will deliver meaningful value to society based on our imaging technologies

Policy

- Further accelerate growth in sensing, materials and components, healthcare (modality), and industrial print, where progress is in line with DX2022 (ongoing)
- Improve profitability in the Office and Production Print Business (FY2022-FY2023)
- Complete business portfolio transformation (medium term, complete by FY2025)
- Make specific policies to realize the five material issues toward 2030 (long term)

Basic Approach

- Set and implement achievable targets
- Prioritize cash flows
- Present our life-sized capability and prioritize dialogue with stakeholders

FY2021
Performance Overview
and
FY2022
Earnings Forecast
Summary



FY2021 Performance | Summary



Full-Year Revenue

While demand recovered from the previous year, when the impact of COVID-19 was significant, excluding FOREX, revenue was on par with the previous year owing mainly to the impact of tight semiconductor supply, prolonged logistics transportation periods, accidents at a toner factory, etc.

Full-Year Operating Profit and Cash Flows

- Despite spike in freight costs and component expenses, the full-year operating loss shrank after excluding impairment loss (¥10.9 billion)
- Generated a profit in Q4 for the first time in three quarters, after excluding impairment losses (¥10.9) billion) and reduction in accounts receivable (-¥9.2 billion)
- Negative FCF owing to the loss, as well as increased inventories from growth in order backlog, etc.
- Period-end dividend was unchanged from previous forecast ¥ 15 per share (¥ 30 per share annually) [¥ billions]

	FY2021 12M	FY2020 12M	YoY	YoY (W/O Forex)	FY2021 Q4	FY2020 Q4	YoY	YoY (W/O Forex)
Revenue	911.4	863.4	+6%	+1%	249.9	248.5	+1%	-4%
Gross Profit	392.7	374.7	+5%	-1%	102.6	110.4	-7%	-11%
Gross Profit ratio	43%	43%	-0pt		41%	44%	-3pt	
SG & A	404.9	389.7	+4%	+0%	104.2	100.3	+4%	+0%
Operating Profit	-22.3	-16.3	_	-	-12.1	8.3	_	_
Profit attributable								
to owners of the Company	-26.1	-15.2	_	-	-12.9	5.4	_	_
FCF	-13.6	43.7	_		-3.9	35.9	_	
FOREY IV1								
FOREX [Yen]								
USD	112.38	106.06	+6.32		116.20	105.90	+10.30	
EUR	130.56	123.70	+6.86		130.39	127.69	+2.70	

FY2021 Performance | Overview



Achievements

- Achieved increases in revenue and profits in line with initial targets in the Industry Business, driven by sensing and materials and components (excluding impairment loss at imaging-IoT solution subsidiary)
- Industrial print and healthcare (modality) also achieved increases in revenue and profits in line with initial targets
- Kept SG&A at the \$100 billion level quarterly as the Company overall (y-o-y increase = FOREX impact)
- Benefits from structural reforms conducted in previous year in office and production print were in line with plans
- Increased orders in response to robust recovery in demand in office and production print
- In DW-DX, revenue continued to increase, particularly for workflow solutions and managed IT services
- Developed our partner strategies (DW-DX, healthcare, QOL, imaging-IoT solution (FORXAI), etc.)

Things we did not achieve

- Supply shortages, mainly in office and production print, owing to tight semiconductor supply, prolonged logistics transportation periods, and accidents at a toner factory
- Although we adjusted some prices, expenses increased and profit decreased owing to the spike in logistics costs (including higher air freight) and component expenses
- In DW-DX, solution sales related to office print decreased owing to supply shortages, and there
 were supply shortages of procured items that use semiconductors
- In Precision medicine, growth slowed owing to the impact of COVID-19
- There were delays in initiative utilizing external capital for businesses with low profit

FY2021 Performance | Revenue & Operating Profit by Segment




Revenue	FY2021 12M	FY2020 12M	YoY	YoY (W/O Forex)	FY2021 Q4	FY2020 Q4	YoY	YoY (W/O Forex)
Digital Workplace	465.4	465.2	+0%	-5%	131.7	128.9	+2%	-3%
Professional Print	194.7	169.6	+15%	+8%	53.8	50.8	+6%	+1%
Healthcare	109.9	109.1	+1%	-2%	25.6	35.5	- 28%	-30%
Industry	139.2	118.2	+18%	+14%	37.9	32.8	+16%	+12%
Sensing	42.4	32.3	+31%	+23%	11.2	9.6	+16%	+9%
Materials and Components	84.2	73.7	+14%	+13%	22.5	19.6	+15%	+12%
Imaging-IoT solutions	12.6	12.2	+3%	-0%	4.2	3.5	+20%	+19%
Corporate, etc.	2.1	1.3	+64%	+73%	1.0	0.5	+98%	+101%
Company overall	911.4	863.4	+6%	+1%	249.9	248.5	+1%	-4%

Operating profit/OPM	FY202	0	FY2019 12M	YoY	YoY (W/O Forex)	FY202 Q4	0	FY2019 Q4	YoY	YoY (W/O Forex)
Digital Workplace	-6.2	_	-2.7	_	_	2.8	2.1%	3.5	- 20%	-23%
Professional Print	1.0	0.5%	-7.9	_	_	0.5	1.0%	0.9	- 43%	-122%
Healthcare	-20.3	_	-6.4	_	-	-10.5	_	0.7	_	_
Industry	18.5	13.3%	15.6	+19%	+12%	-1.2	_	5.8	_	_
Corporate, etc.	-15.3	_	-14.9	-	-	-3.7	_	-2.6	-	-
Company overall	-22.3	_	-16.3	-	-	-12.1	_	8.3	_	_

^{*} Includes ¥1.5 billion impairment of goodwill in Professional Print, ¥9.2 billion of reduction in accounts receivable in Healthcare, and ¥9.4 billion impairment of goodwill in Industry

FY2021 Performance | Factors of Increase/Decrease from FY2020






FY2021 Performance | Factors of Increase/Decrease from Previous Forecast



Operating Profit

Compared with our previous forecast:

- One-time factors had a negative impact of ¥20.1 billion (goodwill impairment, reduction in accounts receivable)
- Worsening businesses had a negative impact of ¥14.8 billion (Digital Workplace, Healthcare)



FY2022 Earnings Forecast | Summary




- Target higher annual revenue and profit based on demand recovery, market growth, and increase investment and strengthen measures on growth fields
- Significant impact in Q1 from tight supply of semiconductors and other components, prolonged logistics transportation periods, and lockdowns in China
- Expect recording of one-time expenses for structural reform in Q2, so losses to continue in H1
- · Increase in FCF from profit improvement and inventory optimization due to elimination of order backlog

	FY2022 Forecast	FY2021 Result	Change	Change rate
Revenue	980.0	911.4	+68.6	+ 8%
Operating Profit	15.0	△ 22.3	+37.3	_
Profit attributable				
to owners of the Company	5.5	△ 26.1	+31.6	_
CAPEX	50.0	42.4		
Depreciation and Amortization Expenses	50.0	55.8		
R&D expenses	63.0	62.7		
FCF	20.0	△ 13.6		
Investment and lending	16.0	0.0		
FOREX [Yen]				
USD	110.0	112.4	△ 2.4	
EUR	125.0	130.6	△ 5.6	

^{*} Depreciation and amortization expenses: IFRS16 right-of- use assets amortization expenses not included.

FY2022 Earnings Forecast | Factors of Increase/Decrease from FY2021






FY2021 Performance | Industry business



- Revenue up 18%. Exceeded initial forecasts. (Also +19% vs. FY19)
- Operating profit +19% (+79% excluding impairment loss)
- Recorded -¥9.4 billion in impairment of goodwill from MOBOTIX AG in imaging-IoT solutions as a one-time factor



Sensing

Revenue +31%

- · Revenue and profits continued to increase
- Light-source color measurement instruments and object color measurement instruments performed well, with some advance shipments

Materials and components

Revenue +14%

- · Revenue and profits increased
- Performance materials remained at a high level for large displays and mobile applications
- · IJ components increased sales for industrial applications
- Optical components were robust in sales for industrial applications, etc.

Imaging-IoT solutions


Revenue +3%

- Impairment of goodwill from MOBOTIX caused by delays in solution development, supply constraints of semiconductor and other components, etc.
- Decrease in thermal cameras, and increase in IP cameras
- Delays to negotiations and orders, partly impacted by the situation in Eastern Europe
- The imaging-IoT platform FORXAI increased partners to more than 100 companies, including strategic partnership

FY2021 Performance | Healthcare Business



- Healthcare performance was driven by device sales and Medical IT in Japan, also grew in India and Asia.
 Revenue up 4% and significant increase in profit
- In Precision medicine, revenue was down 8% and profit decreased. The number of samples increased in genetic testing, despite the impact of resurgence of COVID-19 in the U.S. Revenue decreased owing to reduction in accounts receivable. In drug discovery support, pharmaceutical development research and preclinical trials increased
- Operating profit decreased ¥13.9 billion



Reduction in accounts receivable in precision medicine

As part of preparation for listing REALM, the recoverable amount of accounts receivable for Ambry Genetics, a subsidiary of REALM IDx, has been revised based on the recent actual recoverable rate, resulting in reduction in accounts receivable and revenue of ¥9.2 billion

Background / Issues

- Since 2020, there has been an increasing trend for private insurance companies to make it on the condition that insurance reimbursement requires application approval by hospitals (physicians) in advance
- Application processing is more complex for Ambry, which has a wide range of testing options
- The administrative burden on hospitals increased, partly because of the COVID-19 pandemic
- ⇒ Application errors, missed applications by deadlines occurred
- ⇒ Some testing were not reimbursed by insurance companies (unable to recover accounts receivable)


Counter-measures


The Company will provide application processing support software to hospitals, and strengthen application support and accelerate the rollout by sales and support teams

FY2021 Performance | Digital Workplace Business



- In Office, despite a recovery in hardware demand, there were supply shortages owing to production shortages caused by shortage of semiconductor, etc., and the impact of prolonged logistics transportation period. The non-hard (toner, etc.) was recovered as expected. Revenue down 1% with an order backlog of approximately ¥51.5 billion
- In DW-DX, although recurring revenue performed well, solutions sales related to office print decreased and there were supply shortages of procured items due to tight semiconductor supply, resulting in weak growth. Revenue was up 5%
- Operating profit was impacted by the spike in logistics costs and component expenses, despite the benefits of structural reform and some price revisions. ¥3.5 billion decrease in profit






FY2021 Performance | Professional Print Business



- In production print, commercial print demand recovered, particularly at medium-to-large-sized printing companies in Europe and America. Non-hard recovered and hardware demand also recovered accordingly. As a result, revenue was up 12% and the order backlog was approximately ¥8.0 billion
- In industrial print, performance was good amid strong demand and the shift to digital printing. Revenue increased 46%, exceeding the initial forecast.
- Operating profit increased ¥8.9 billion, driven by revenue recovery (PP) and growth (IP) (including an impairment loss of ¥1.5 billion at a Marketing services subsidiary).



FY2022 Earnings Forecast



FY2022 Earnings Forecast | Perceptions of Environment



Perceptions of environment surrounding our businesses

FOREX

Comprehensively taking into consideration recent actual rates and market forecasts (forecast rate: ¥110/USD, ¥125/EUR)

COVID-19

Expect economic activity to normalize in many countries, but uncertainty remains owing to variants. Greater impact from lockdowns in China owing to zero COVID-19 policy

Semiconductor shortage

Expect the pace of demand growth to outstrip supply capacity increases, resulting in continued shortages through 2022, particularly in semiconductors for automotive applications

Prolonged logistics transportation periods /Spike in logistics cost

Expect tight logistics to continue, as there remains little sign of its improvement, namely port congestion, quarantine measures, and labor shortages

Situation in Ukraine and Europe

Expect GDP to exceed pre-COVID-19 levels in North America, Japan, and major countries in the EU, but global economic forecast revised downward based on the situation in the Ukraine

Spike in materials and energy prices

Expect increases in crude oil and energy prices owing to the situation in the Ukraine, increases in prices of materials owing partly to a decrease in exports from China, and spike in silver market owing to speculator

FY2022 Earnings Forecast | Perceptions of Business Environment



	Environment impacting our bus	sinesses
	Perception of market / demand environment	Supply environment
Digital Workplace	 Non-hard demand to increase compared with FY2021 as the return of employees to the office at client companies becomes established Robust hardware demand. Market to be limited by supply constraints Growth in IT/DX demand in the office environment to continue 	
Professional Print	 Acceleration of the shift from analog printing to digital printing in both commercial and industrial printing Demand to recover as economic activities normalize in North America and Europe 7-10% growth in MPP/HPP market, which the Company is focusing on 	 Significant impact from lockdowns in China in Q1 Longer logistics and transportation
Healthcare	 Promoting the use of high value-added imaging in Healthcare (Modality) In Precision medicine, increasing the number of patients in the U.S. and restarting clinical trials 	transportation periods/component shortages to continue • Toner shortages to be resolved
Industry	 Moderate recovery in smartphone market Growth in large display market. Continuing shift to China (total area: +5%, including ultra-wide: +20%) Increase in demand for high-performance ultra-thin film for mobile applications IP cameras to recover, but European market to be impacted by the situation in Eastern Europe 	



FY2022 priority initiatives

Businesses with stable profit

Office Production print

- Implement structural reforms to make sales/services/management more efficient and higher quality (Q2: one-time expenses of ¥6.0 billion, benefit in current period: ¥3.5 billion, annual benefit: ¥6.5 billion)
- Revise manufacturing strategies in consideration of geopolitical risk (including partner strategies) in the medium to long-term perspective

Core businesses

Sensing,
Performance materials,
IJ components,
Healthcare (Modality)

- Continue strengthening business development in growth areas
- Conduct M&A (sensing), make selective and strategic capital investments (performance materials), generate results from strategic partnerships (healthcare), and invest in human resources, in the medium- to long-term perspective

Strategic new businesses

Precision medicine, Imaging-IoT solutions, DW-DX, Industrial print

- Continue IPO preparations while watching for the appropriate opportunity (precision medicine), maximize synergies within the Group (imaging-IoT solutions), and accelerate business growth to capture the shift to digital printing (industrial print)
- Focus on generating results based on previous investments in human resources and development, and make selective investments in advanced development

Businesses with low profit

Optical components, Marketing services

- Continue to promote measures with the utilization of external capital in mind
- Aggregate resources in upstream part of value chain

FY2022 Earnings Forecast | Revenue & Operating Profit by Segments



Revenue	FY2022 Forecast	FY2021 Result	Change	Change rate
Digital Workplace	495.0	465.4	+29.6	+6%
Professional Print	210.0	194.7	+15.3	+8%
Healthcare	125.0	109.9	+15.1	+14%
Industry	150.0	139.2	+10.8	+8%
Sensing	42.0	42.4	- 0.4	-1%
Materials and Components	93.0	84.2	+8.8	+10%
Imaging-IoT solutions	15.0	12.6	+2.4	+19%
Corporate, etc.	0.0	2.1	- 2.1	-100%
Company overall	980.0	911.4	+68.6	+8%

Operating profit/OPM	FY2022 Forecast		FY2021 Result		Change	Change rate
Digital Workplace	3.5	0.7%	△ 6.2	_	+9.7	_
Professional Print	5.0	2.4%	1.0	0.5%	+4.0	+383%
Healthcare	△ 6.5	_	△ 20.3	_	+13.8	_
Industry	30.0	20.0%	18.5	13.3%	+11.5	+62%
Corporate, etc.	△ 17.0	_	△ 15.3	_	- 1.7	_
Company overall	15.0	1.5%	△ 22.3	_	+37.3	

FY2022 Earnings Forecast | Capital Policy



Dividend Policy of the Company

The Company's basic policy regarding the determination of dividends of surplus, etc., is to endeavor to enhance shareholder returns, with dividends as the foundation, while comprehensively taking into consideration consolidated results, investment in growth areas, **cash flows**, and other factors.

We will make appropriate decisions concerning share buybacks as one of our policies for returning profits, while taking into consideration the financial position of the Company, share price trends, and other factors.

Dividend Forecast for FY2022


In accordance with the above dividend policy, we expect to reduce the dividend by \frac{\pmathbb{10}}{\share compared with FY2021 and pay a dividend for FY2022 as follows.

¥20/share (interim dividend of ¥10 and year-end dividend of ¥10)





Appendix



Appendix Financial Result – Overview



					r.	51110113]
	FY2021	FY2020		FY2021	FY2020	
	12M	12M	YoY	4Q	4Q	YoY
Revenue	911.4	863.4	+ 6%	249.9	248.5	+ 1%
Gross Profit	392.7	374.7	+ 5%	102.6	110.4	- 7%
Gross Profit ratio	43.1%	43.4%	-0.3pt	41.0%	44.4%	-3.4pt
SG & A	404.9	389.7	+ 4%	104.2	100.3	+ 4%
Other income and costs	-10.1	-1.2		-10.5	-1.8	
Operating Profit	-22.3	-16.3	-	-12.1	8.3	_
Operating Profit ratio	-		-	-	3.4%	
Finance income and costs	-1.3	-3.7		0.6	0.1	
Profit before tax	-23.6	-20.0	-	-11.5	8.5	_
Profit before tax ratio	_	_	-	_	3.4%	
Profit attributable to owners of the Company	-26.1	-15.2	-	-12.9	5.4	_
Profit attributable to owners of the Company ratio	_	_	-	_	2.2%	
EPS [Yen]	-52.9	-30.7		-26.1	11.0	
CAPEX	42.4	57.7		14.8	27.7	
Depreciation and Amortization Expenses *	55.8	57.2		14.0	14.4	
R&D expenses	62.7	65.0		15.5	16.5	
FCF	-13.6	43.7		-3.9	35.9	
Investment and lending	0.0	9.3		0.0	0.6	
FOREX [Yen] USD	112.38	106.06	+6.32	116.20	105.90	+10.30
EUR	130.56	123.70	+6.86	130.39	127.69	+2.70

 $^{{}^*\} Depreciation\ and\ amortization\ expenses: IFRS16\ right-of-\ use\ assets\ amortization\ expenses\ not\ included.$

Appendix SG&A-Other Income/ Expenses-Finance Income/Loss



FY2021 FY2020 12M 12M SG&A Selling expenses – variable R&D expenses 62.7 65.0 Personnel expenses 194.7 186.1		FY2021 Q4 10.8	FY2020 Q4	YoY
Selling expenses – variable 36.4 33.8 R&D expenses 62.7 65.0		10.8		
R&D expenses 62.7 65.0		10.8		
	2.4		9.2	+1.6
Personnel eynenses	- 2.4	15.5	16.5	- 1.1
194.7 186.1	+8.6	49.8	48.0	+1.8
Others 111.1 104.8	+6.3	28.2	26.5	+1.6
SG&A total 404.9 389.7	+15.2	104.2	100.3	+3.9
* Forex impact: 15.1bn. (Actual: 0.1bn.)		3.8b	n. (Actual: 0.1bn.)	
Other income:				
Other income total 10.3 14.0	- 3.8	4.1	5.1	- 0.9
Other expenses				
Loss on sales of property, plant and equipment 1.9	+0.5	0.4	0.5	- 0.1
Impairment losses on property 0.0	- 0.8	0.0	0.3	- 0.2
Impairment of goodwill 10.9	+10.9	10.9	-	+10.9
Business structure improvement costs 1.4 8.1	- 6.7	0.4	4.4	- 4.0
Other expenses 6.2 4.9	+1.2	2.9	1.7	+1.2
Other expenses total 20.4 15.3	+5.1	14.6	6.9	+7.7
Finance income/loss:				
Interest income/Dividends received/Interest expense -3.3 -3.8	+0.5	-1.0	-1.1	+0.1
Foreign exchange gain/loss (net) 1.3 0.6	+0.7	1.3	1.0	+0.4
Others 0.7 -0.5	+1.2	0.3	0.2	+0.0
Finance income/loss, net -1.3 -3.7	+2.4	0.6	0.1	+0.5

Appendix Operating Profit Analysis



Comparison of Y on Y FY21/12M vs. FY20/12M	Digital Workplace	Professional Print	Healthcare	Industry	corporate, etc.	Total
[Factors]						
Forex impact	+3.1	+2.9	- 1.0	+1.0	- 0.2	+5.7
Sales volume change, and other, net	- 17.5	+4.4	- 4.5	+13.9	+0.4	- 3.3
Price change	+1.9	- 0.3	- 0.3	- 0.7	_	+0.6
SG&A change, net	+4.8	+3.6	- 7.5	- 1.6	+0.5	- 0.1
Other income and expense	+4.2	- 1.8	- 0.5	- 9.8	- 1.1	- 8.9
[Operating Profit]						
Change, YoY	- 3.5	+8.9	- 13.9	+2.9	- 0.4	- 6.0

Comparison of Y on Y FY21/Q4 vs. FY20/Q4	Digital Workplace	Professional Print	Healthcare	Industry	corporate, etc.	Total
[Factors]						
Forex impact	+0.1	+0.7	- 1.0	+0.4	- 0.0	+0.2
Sales volume change, and other, net	- 5.7	- 1.0	- 8.6	+2.8	- 0.1	- 12.7
Price change	+1.4	- 0.0	- 0.2	- 0.3	_	+0.8
SG&A change, net	+0.3	+0.8	- 0.5	- 0.2	- 0.5	- 0.1
Other income and expense	+3.2	- 0.9	- 0.9	- 9.6	- 0.5	- 8.7
[Operating Profit]						
Change, YoY	- 0.7	- 0.4	- 11.2	- 7.0	- 1.2	- 20.5

Appendix Consolidated Statements of Financial Position




	Mar 2020	Mar 2021	Mar 2022		Mar 2020	Mar 2021	Mar 2022
Cash and cash equivalents	89.9	123.8	117.7	Trade and other payables	162.9	185.8	182.1
Trade and other receivables	260.9	262.8	280.2	Bonds and borrowings	289.3	315.3	354.3
Inventories	162.6	156.9	185.7	Lease liabilities	114.2	95.4	94.3
Other current assets	37.8	38.4	35.3	Othe liabilities	176.6	152.6	145.9
Total current assets	551.2	582.0	618.9	Total liabilities	743.0	749.0	776.6
Property, plant and equipment	309.5	292.5	287.7	Equity attributable to owners of	523.7	539.9	549.8
Goodwill and intangible asseets	337.8	347.5	354.1	the Company	323.7	339.9	545.0
Othe non-current assets	78.4	77.7	77.4	Non-controlling interests	10.0	10.8	11.7
Total non-current assets	725.6	717.7	719.3	Total equity	533.8	550.7	561.5
Total assets	1,276.8	1,299.8	1,338.1	Total liabilities and equity	1,276.8	1,299.8	1,338.1

	Mar 2020	Mar 2021	Mar 2022
Equity ratio (%)	41.0	41.5	41.1
Equity ratio for company rating (%)	44.9	45.3	44.8
D/E ratio	0.77	0.76	0.82

Appendix Consolidated Financial Statements | Consolidated Statements of Cash Flows




	EV10 12M	FY20 12M	EV21 12M
	FT19 IZW	FTZU TZIVI	FTZT TZIVI
Profit (loss) before tax	0.3	-20.0	-23.6
Depreciation and amortization expenses	77.1	77.6	75.8
(Increase) decrease in trade and other receivables	-0.2	14.9	4.0
(Increase) decrease in inventories	-23.2	13.8	-17.3
Increase (decrease) in trade and other payables	-4.8	-4.8	2.1
Othes	-19.0	-3.4	-3.5
Cash flows from operating activities	30.1	78.1	37.4
Purchase of property, plant and equipment	-36.6	-25.7	-41.3
Purchase of intangible assets	-12.9	-14.5	-19.8
Purchase of investments in subsidiaries	-6.4	-5.1	-
Others	5.9	10.9	10.0
Net cash provided by (used in) investing activities	-50.0	-34.3	-51.0
Free cash flows	-19.9	43.7	-13.6



Appendix Consolidated Financial Statements | Quarterly Cash Flow from Operating Activities





Appendix FOREX Impact on Revenue and Operating Profit



[FOREX:¥]

[Impact, Sensitivity: ¥ billions]

	FY20	FY21	YoY In	npact	FX Sensi	tivity*2
	12M	12M	Revenue	OP	Revenue	OP
USD	106.06	112.38	+16.4	- 1.7	+2.7	- 0.3
EUR	123.70	130.56	+10.2	+4.5	+1.5	+0.4
GBP	138.68	153.56	+3.0	- 0.1	+0.2	+0.1
European Currency*1	_	_	+14.6	+4.3	+2.0	+0.6
CNY	15.67	17.51	+6.1	+2.2	+3.3	+1.3
Other	_	_	+4.6	+1.0	_	_
Exchange contract effect	_	_	- 0.1	- 0.1	_	_
Total	_	_	+41.6	+5.7	_	_

^{*1} European currency: Currencies used in Europe including EUR/GBP

^{*2} FOREX Sensitivity: FOREX impact at ¥1 change (annual)

Appendix Quarterly Financial Results: Segments



			FY19					FY20					FY21		
[Revenue]	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M
Digital Workplace Business	135.0	139.1	139.5	135.4	549.0	94.6	116.7	125.0	128.9	465.2	121.2	104.9	107.6	131.7	465.4
Office	116.4	120.9	119.6	116.6	473.5	78.3	98.2	104.2	107.9	388.6	102.9	85.5	87.7	108.8	385.0
DW-DX	18.5	18.2	19.9	18.8	75.5	16.3	18.5	20.8	21.1	76.7	18.2	19.4	19.9	22.9	80.5
Professional Print Business	50.6	52.7	55.4	51.4	210.1	31.8	41.7	45.3	50.8	169.6	47.9	45.6	47.4	53.8	194.7
Production print	34.2	35.4	37.5	33.5	140.6	20.4	27.1	29.5	32.7	109.8	30.3	29.2	30.6	33.2	123.3
Industrial print	3.8	5.8	5.1	6.0	20.6	2.9	4.3	4.8	6.3	18.4	5.9	6.2	6.1	8.5	26.7
Marketing services	12.6	11.5	12.8	11.9	48.8	8.4	10.2	11.0	11.7	41.4	11.7	10.2	10.8	12.1	44.7
Healthcare Business	25.9	33.8	25.9	33.0	118.5	20.5	24.9	28.2	35.5	109.1	25.2	31.0	28.2	25.6	109.9
Healthcare	18.6	26.4	18.1	24.7	87.9	16.4	19.1	20.0	27.9	83.4	17.2	22.6	20.3	26.2	86.3
Precision medicine	7.2	7.4	7.7	8.3	30.6	4.1	5.9	8.2	7.6	25.7	8.0	8.4	7.9	-0.7	23.6
Industry Business	30.0	29.8	28.5	28.9	117.2	26.1	27.9	31.5	32.8	118.2	35.2	33.3	32.8	37.9	139.2
Sensing	6.6	6.7	7.3	7.0	27.5	7.1	7.6	8.0	9.6	32.3	12.2	9.7	9.3	11.2	42.4
Materials and Components	21.0	20.5	18.9	18.5	78.8	16.1	17.6	20.5	19.6	73.7	20.5	20.8	20.5	22.5	84.2
Imaging-IoT solutions	2.5	2.7	2.3	3.4	10.9	2.9	2.8	3.0	3.5	12.2	2.6	2.9	2.9	4.2	12.6
Corporate etc.	0.3	0.3	0.3	0.5	1.3	0.2	0.3	0.2	0.5	1.3	0.3	0.4	0.5	1.0	2.1
Company overall	241.7	255.7	249.5	249.1	996.1	173.2	211.5	230.2	248.5	863.4	229.9	215.2	216.4	249.9	911.4
【Operating Profit】	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M
Digital Workplace Business	5.5	7.8	4.3	0.1	17.7	-9.6	0.3	3.1	3.5	-2.7	1.1	-5.4	-4.6	2.8	-6.2
Professional Print Business	1.1	1.0	2.9	-0.7	4.4	-7.1	-1.7	0.0	0.9	-7.9	1.0	0.5	-1.0	0.5	1.0
Healthcare Business	-2.1	-1.2	-0.4	-0.6	-4.4	-4.7	-1.8	-0.5	0.7	-6.4	-3.2	-2.1	-4.5	-10.5	-20.3
Industry Business	3.2	3.7	4.2	3.2	14.4	2.8	2.2	4.8	5.8	15.6	8.0	6.5	5.2	-1.2	18.5
Corporate etc.	-7.0	-6.5	-5.9	-4.5	-23.9	-4.1	-4.2	-4.0	-2.6	-14.9	-3.7	-4.2	-3.7	-3.7	-15.3
Company overall	0.6	4.9	5.1	-2.4	8.2	-22.6	-5.2	3.3	8.3	-16.3	3.1	-4.7	-8.6	-12.1	-22.3

Appendix Quarterly Financial Results: Industry Business



			FY19					FY20					FY21		
[Revenue]	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M
Industry Business	30.0	29.8	28.5	28.9	117.2	26.1	27.9	31.5	32.8	118.2	35.2	33.3	32.8	37.9	139.2
Sensing	6.6	6.7	7.3	7.0	27.5	7.1	7.6	8.0	9.6	32.3	12.2	9.7	9.3	11.2	42.4
Materials and Components	21.0	20.5	18.9	18.5	78.8	16.1	17.6	20.5	19.6	73.7	20.5	20.8	20.5	22.5	84.2
Performance materials	12.0	11.3	10.2	10.8	44.3	9.8	11.6	13.3	12.0	46.8	13.2	12.8	12.7	13.6	52.2
Optical components	4.8	5.3	5.2	4.4	19.7	3.8	3.2	4.0	3.6	14.5	3.8	4.4	4.2	4.8	17.2
IJ components	4.2	3.9	3.5	3.2	14.8	2.5	2.8	3.2	4.0	12.5	3.5	3.6	3.6	4.1	14.8
Imaging-IoT solutions	2.5	2.7	2.3	3.4	10.9	2.9	2.8	3.0	3.5	12.2	2.6	2.9	2.9	4.2	12.6
Imaging-IoT solutions	1.9	2.0	1.6	2.2	7.6	2.7	2.3	2.0	2.0	9.0	2.3	2.4	2.1	2.1	8.8
Visual solutions	0.6	0.8	0.7	1.2	3.3	0.2	0.4	1.0	1.6	3.2	0.3	0.5	0.8	2.2	3.9

[Operating Profit]	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M	Q1	Q2	Q3	Q4	12M
Industry Business	3.2	3.7	4.2	3.2	14.4	2.8	2.2	4.8	5.8	15.6	8.0	6.5	5.2	-1.2	18.5

Appendix Digital Workplace/Professional Print | Sales Trends - Regional



■ Composition of revenue by region (in yen)

	FY19					FY	20		FY21				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
Japan	12%	13%	13%	14%	15%	14%	14%	14%	12%	13%	14%	14%	
North America	34%	33%	33%	33%	33%	32%	31%	31%	32%	31%	31%	30%	
EU	36%	34%	37%	37%	35%	36%	36%	37%	37%	35%	35%	36%	
China	6%	6%	5%	4%	8%	8%	8%	7%	7%	9%	7%	6%	
Others	12%	13%	12%	12%	10%	11%	11%	11%	12%	13%	13%	13%	

■ Change in revenue by region (w/o FOREX)

	FY19					FY	20		FY21				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	
Japan	-8%	+4%	+1%	-3%	-19%	-18%	-14%	-11%	+12%	-9%	-7%	-2%	
North America	-2%	-2%	-3%	-12%	-34%	-27%	-24%	-20%	+27%	-12%	-14%	-5%	
EU	-2%	-1%	+6%	-7%	-31%	-23%	-19%	-17%	+28%	-13%	-18%	-1%	
China	-4%	-1%	-8%	-40%	-4%	+1%	+7%	+16%	+15%	-1%	-21%	-13%	
Others	-7%	+2%	+5%	-6%	-35%	-32%	-25%	-20%	+37%	+4%	-8%	+9%	

Percentage of color in sales of hardware

		FY	19			FY	20			FY	21	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Office	72%	73%	72%	75%	69%	76%	75%	74%	74%	72%	73%	77%
Professional Print	78%	82%	76%	80%	75%	80%	80%	81%	79%	82%	80%	79%

Appendix Office Printing | Trends of Unit Sales and Non-hard Revenue



■ Transition of Office MFP Unit Sales Y o Y

		FY	19			FY	20			FY	21	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
A3 Color MFP	93%	99%	102%	93%	72%	84%	92%	92%	132%	62%	55%	103%
A3 Monochrome MFP	95%	95%	94%	60%	76%	89%	98%	140%	117%	83%	65%	75%
A3 MFP overall	94%	97%	99%	79%	74%	86%	94%	107%	126%	71%	59%	91%

■ Transition of Non-hard Revenue Y o Y

		FY	19			FY	20			FY	21	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Revenue of non-hard	62.4	60.5	62.3	60.1	42.1	48.9	53.1	51.1	53.5	51.3	52.8	54.1
Ratio of non-hard	53%	50%	52%	51%	53%	50%	51%	47%	52%	60%	60%	49%

■ Transition of Regional Non-hard Revenue w/o Forex Y o Y

	FY19					FY	20					
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Japan	97%	100%	99%	98%	85%	90%	94%	92%	108%	98%	97%	97%
U.S.	99%	99%	98%	95%	62%	73%	78%	81%	124%	103%	94%	101%
Europe	96%	100%	102%	97%	66%	82%	83%	78%	126%	101%	93%	104%
China	105%	114%	96%	72%	107%	105%	115%	140%	102%	105%	65%	79%
India	115%	117%	101%	102%	52%	68%	98%	113%	141%	151%	130%	96%
Overall	98%	98%	99%	97%	69%	80%	85%	84%	120%	101%	94%	101%

Appendix Production Print | Trends of Unit Sales and Non-hard Revenue



■ Transition of Production Print Unit Sales Y o Y

		FY	19			FY	20		FY21			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Color	100%	97%	102%	72%	51%	73%	65%	100%	138%	83%	99%	71%
Monochrome	107%	87%	89%	76%	59%	68%	71%	95%	122%	83%	90%	83%
Overall	102%	93%	97%	73%	54%	71%	67%	99%	132%	83%	96%	74%

■ Transition of Non-hard Revenue Y o Y


	FY19					FY	20		FY21			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Revenue of non-hard	20.3	19.9	21.5	19.8	12.2	14.8	17.9	17.5	18.3	17.9	18.3	19.6
Ratio of non-hard	59%	56%	57%	59%	60%	55%	60%	53%	60%	61%	60%	59%

■ Transition of Regional Non-hard Revenue w/o Forex Y o Y

		FY	19			FY	20		FY21			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Japan	97%	98%	94%	93%	76%	82%	88%	87%	107%	93%	75%	90%
U.S.	96%	101%	96%	94%	52%	67%	77%	82%	146%	111%	100%	110%
Europe	97%	97%	100%	100%	64%	77%	79%	78%	138%	121%	98%	110%
China	112%	121%	116%	92%	113%	117%	140%	138%	156%	118%	70%	92%
India	117%	121%	116%	105%	34%	71%	105%	113%	245%	151%	116%	101%
Overall	102%	99%	101%	99%	62%	75%	84%	88%	141%	115%	96%	106%

Appendix Revenue and KPI Trends of Ambry Genetics and Invicro





Appendix Segment information



Befo	re March 31, 2021		After April 1, 2021					
Digital Workplace Business	■ Office(OP) ■ IT service solutions(ITS) ■ Workplace Hub(WPH)		Digital Workplace Business	■ Office(OP) ■ DW-DX(DW-DX)				
Professional Print Business	Production print(PP)Industrial print(IP)Marketing services(MS)		Professional Print Business	Production print(PP)Industrial print(IP)Marketing services(MS)				
Healthcare Business	■ Healthcare(HC) ■ Precision medicine(APM)		Healthcare Business	■ Healthcare(HC) ■ Precision medicine(APM)				
	Sensing			Sensing				
	■ Measuring instruments(MI)			■ Measuring instruments(MI)				
	Materials and components	Ind		Materials and components				
Industry Business	Performance materials(PM)Optical components(OC)IJ components(IJ)		Industry Business	 Performance materials(PM) Optical components(OC) IJ components(IJ) 				
	Imaging-IoT solutions			Imaging-IoT solutions				
	Imaging-IoT solutions(IIS)Visual solutions(VS)			■ Imaging-IoT solutions(IIS)■ Visual solutions(VS)				
Corporate, etc., QO	Corporate, etc., QOL							

Appendix Business Portfolio Management Positioning (Extract from November 2020 IR Day materials)



Growth potential (sales growth rate) Strategic new businesses Core businesses Precision medicine Sensing **Imaging IoT solutions Inkjet components** Workplace Hub/IT Services Performance materials Legend **Industrial** print **Production print** Industry Healthcare (existing) Healthcare **Digital Workplace Marketing services Professional Print Office Printing Optical components** Businesses with stable profit **Businesses with low profit** Profitability (profit ratio), capital efficiency (ROIC) Capital costs Medium-term hurdle rate matched to characteristics of each business

Glossary



- MFP (Multi Functional Peripheral) Speed Segment: Digital Workplace Business
 Seg. 1 to 20ppm, Seg.2 21–30ppm, Seg.3 31–40ppm, Seg.4 41–69ppm, Seg.5 70~ppm (A4 vertical, minute speed)
- Color production print Machine Segments: Professional Print Business
 ELPP (Entry Light Production Print) Monthly printing volume: 1-0.3 million sheets for low-priced products mainly for large companies' centralized printing rooms
 LPP (Light Production Print) Monthly printing volume: 0.1-0.3 million sheets for commercial printers
 MPP (Mid Production Print) Monthly printing volume: 30-1 million sheets for commercial printing products
 HPP (Heavy Production Print) Monthly printing volume: 1 million sheets or more for commercial printing products
- RNA (ribonucleic acid)Testing: Healthcare Business

 Testing to identify changes in mRNA structure in the primary transcript of DNA(deoxyribonucleic acid).

 Analysis of transcript mRNA can provide more detailed test results on DNA mutations that used to be considered of undetermined clinical significance in conventional DNA testing.
- CARE Program (Comprehensive Assessment, Risk & Education): Healthcare Business

 Program to provide total support for effective pick-up and genetic diagnostics of the high-risk group of genetic breast cancer.
- FORXAI: Imaging IoT Solutions Business
 FORXAI is an imaging IoT platform that accelerates digital transformation of society together with customers and partners.

